Recent Quotes (30 days)

You have no recent quotes
chg | %

Pivot Pharmaceuticals Inc  

(Public, OTCMKTS:PVOTF)   Watch this stock  
Find more results for OTC:NEUKF
May 22 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.40
Open     -
Vol / Avg. 0.00/6,990.00
Mkt cap 7.59M
P/E     -
Div/yield     -
EPS -0.01
Shares 11.58M
Beta -13.19
Inst. own     -

Key stats and ratios

Q4 (Oct '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -6931.72% -
Return on average equity - -
CDP Score - -


1275 6th Ave W
+1-604-8057783 (Phone)
+1-604-2250588 (Fax)


Pivot Pharmaceuticals Inc, formerly Neurokine Pharmaceuticals Inc., is a biopharmaceutical company. The Company is engaged in the development and repositioning of existing drugs to treat diseases that focus primarily on women’s health. The Company's drug products are indicated mainly for the treatment of dysmenorrhea, LUTS, kidney stones, menopausal symptoms (hot flushes), narcotics withdrawal, smoking cessation, migraine and dementia. The Company's product pipeline includes P-001, P-002 and P-003. Its product P-001 is indicated for the treatment of dysmenorrhea, female lower urinary tract symptoms (LUTS) and female kidney stones. Its P-002 is indicated for the treatment of menopausal symptoms, narcotics withdrawal and smoking cessation. Its P-003 is indicated for the treatment of migraine and dementia.